SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-196206
Filing Date
2021-06-22
Accepted
2021-06-22 16:09:55
Documents
13
Period of Report
2021-06-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d130231d8k.htm   iXBRL 8-K 37008
2 EX-3.1 d130231dex31.htm EX-3.1 4417
  Complete submission text file 0001193125-21-196206.txt   167101

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20210621.xsd EX-101.SCH 2934
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20210621_lab.xml EX-101.LAB 18125
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20210621_pre.xml EX-101.PRE 11433
6 EXTRACTED XBRL INSTANCE DOCUMENT d130231d8k_htm.xml XML 3421
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 211035313
SIC: 2834 Pharmaceutical Preparations